Risk of secondary progressive multiple sclerosis: A longitudinal study.

Adult Disease Progression Female Humans Immunologic Factors / pharmacology Longitudinal Studies Male Multiple Sclerosis, Chronic Progressive / drug therapy Multiple Sclerosis, Relapsing-Remitting / drug therapy Risk Severity of Illness Index
SPMS disease modifying therapies multiple sclerosis prediction prognostics

Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
01 2020
Historique:
pubmed: 10 8 2019
medline: 18 11 2020
entrez: 10 8 2019
Statut: ppublish

Résumé

The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. The aim of this study was to determine the demographic, clinical and paraclinical features that influence the risk of conversion to secondary progressive multiple sclerosis. Patients with adult-onset relapsing-remitting multiple sclerosis and at least four recorded disability scores were selected from MSBase, a global observational cohort. The risk of conversion to objectively defined secondary progressive multiple sclerosis was evaluated at multiple time points per patient using multivariable marginal Cox regression models. Sensitivity analyses were performed. A total of 15,717 patients were included in the primary analysis. Older age (hazard ratio (HR) = 1.02, Risk of secondary progressive multiple sclerosis increases with age, duration of illness and worsening disability and decreases with improving disability. Therapy may delay the onset of secondary progression.

Sections du résumé

BACKGROUND
The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested.
OBJECTIVE
The aim of this study was to determine the demographic, clinical and paraclinical features that influence the risk of conversion to secondary progressive multiple sclerosis.
METHODS
Patients with adult-onset relapsing-remitting multiple sclerosis and at least four recorded disability scores were selected from MSBase, a global observational cohort. The risk of conversion to objectively defined secondary progressive multiple sclerosis was evaluated at multiple time points per patient using multivariable marginal Cox regression models. Sensitivity analyses were performed.
RESULTS
A total of 15,717 patients were included in the primary analysis. Older age (hazard ratio (HR) = 1.02,
CONCLUSION
Risk of secondary progressive multiple sclerosis increases with age, duration of illness and worsening disability and decreases with improving disability. Therapy may delay the onset of secondary progression.

Identifiants

DOI: 10.1177/1352458519868990 PMID: 31397221
pubmed: 31397221
doi: 10.1177/1352458519868990
doi:

Substances chimiques

Immunologic Factors 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-90

Auteurs

Adam Fambiatos (A)

CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia.

Vilija Jokubaitis (V)

Central Clinical School, Monash University, Melbourne, VIC, Australia The Alfred, Melbourne, VIC, Australia.

Dana Horakova (D)

Department of Neurology and Center of Clinical Neuroscience, General University Hospital and Charles University in Prague, Prague, Czech Republic.

Eva Kubala Havrdova (E)

Department of Neurology and Center of Clinical Neuroscience, General University Hospital and Charles University in Prague, Prague, Czech Republic.

Maria Trojano (M)

Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy.

Alexandre Prat (A)

Hopital Notre-Dame, Montreal, QC, Canada/CHUM and Universite de Montreal, Montreal, QC, Canada.

Marc Girard (M)

Hopital Notre-Dame, Montreal, QC, Canada/CHUM and Universite de Montreal, Montreal, QC, Canada.

Pierre Duquette (P)

Hopital Notre-Dame, Montreal, QC, Canada/CHUM and Universite de Montreal, Montreal, QC, Canada.

Alessandra Lugaresi (A)

IRCCS Istituto delle Scienze Neurologiche di Bologna, UOSI Riabilitazione Sclerosi Multipla, Bologna, Italy/Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy.

Guillermo Izquierdo (G)

Hospital Universitario Virgen Macarena, Sevilla, Spain.

Francois Grand'Maison (F)

Neuro-Rive-Sud, Greenfield Park, QC, Canada.

Pierre Grammond (P)

CISSS de Chaudière-Appalache, Centre-Hospitalier, Levis, Canada.

Patrizia Sola (P)

Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy.

Diana Ferraro (D)

Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy.

Raed Alroughani (R)

Amiri Hospital, Kuwait City, Kuwait.
ORCID: 0000-0001-5436-5804

Murat Terzi (M)

Medical Faculty, Ondokuz Mayis University, Samsun, Turkey.

Raymond Hupperts (R)

Zuyderland Ziekenhuis, Sittard, The Netherlands.

Cavit Boz (C)

TU Medical Faculty, Farabi Hospital, Karadeniz Technical University, Trabzon, Turkey.

Jeannette Lechner-Scott (J)

School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia/Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, NSW, Australia.

Eugenio Pucci (E)

UOC Neurologia, Azienda Sanitaria Unica Regionale Marche, Macerata, Italy.

Roberto Bergamaschi (R)

IRCCS Mondino Foundation, Pavia, Italy.

Vincent Van Pesch (V)

Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Serkan Ozakbas (S)

Dokuz Eylul University, Izmir, Turkey.

Franco Granella (F)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Recai Turkoglu (R)

Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.

Gerardo Iuliano (G)

Ospedali Riuniti di Salerno, Salerno, Italy.

Daniele Spitaleri (D)

Azienda Ospedaliera di Rilievo Nazionale, San Giuseppe Moscati - Avellino, Avellino, Italy.

Pamela McCombe (P)

The University of Queensland, Brisbane, QLD, Australia/Royal Brisbane and Women's Hospital, Herston, QLD, Australia.

Claudio Solaro (C)

Ospedale P.A. Micone, Genova, Italy.

Mark Slee (M)

Flinders University, Adelaide, SA, Australia.

Radek Ampapa (R)

Nemocnice Jihlava, Jihlava, Czech Republic.

Aysun Soysal (A)

Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey.

Thor Petersen (T)

Kommunehospitalet, Arhus, Denmark.

Jose Luis Sanchez-Menoyo (JL)

Hospital de Galdakao-Usansolo, Galdakao, Spain.

Freek Verheul (F)

Groene Hart Ziekenhuis, Gouda, The Netherlands.

Julie Prevost (J)

CSSS Saint-Jérôme, Saint-Jerome, QC, Canada.

Youssef Sidhom (Y)

Department of Neurology, Razi Hospital, Manouba, Tunisia.

Bart Van Wijmeersch (B)

Rehabilitation and MS-Centre Overpelt and Hasselt University, Hasselt, Belgium.

Steve Vucic (S)

Westmead Hospital, Sydney, NSW, Australia.

Edgardo Cristiano (E)

Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Maria Laura Saladino (ML)

Institute of Neurosciences Buenos Aires, Buenos Aires, Argentina.

Norma Deri (N)

Hospital Fernandez, Buenos Aires, Argentina.

Michael Barnett (M)

Brain and Mind Centre, Sydney, NSW, Australia.

Javier Olascoaga (J)

Hospital Universitario Donostia-Instituto de Investigación Sanitaria Biodonostia, San Sebastian, Spain.

Fraser Moore (F)

Jewish General Hospital, Montreal, QC, Canada.

Olga Skibina (O)

The Alfred, Melbourne, VIC, Australia.

Orla Gray (O)

South East Trust, Belfast, UK.

Yara Fragoso (Y)

Universidade Metropolitana de Santos, Santos, Brazil.
ORCID: 0000-0001-8726-089X

Bassem Yamout (B)

American University of Beirut Medical Center, Beirut, Lebanon.

Cameron Shaw (C)

Geelong Hospital, Geelong, VIC, Australia.

Bhim Singhal (B)

Bombay Hospital Institute of Medical Sciences, Mumbai, India.

Neil Shuey (N)

St Vincent's Hospital, Melbourne, VIC, Australia.

Suzanne Hodgkinson (S)

Liverpool Hospital, Sydney, NSW, Australia.

Ayse Altintas (A)

Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey.

Talal Al-Harbi (T)

King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia.

Tunde Csepany (T)

Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Bruce Taylor (B)

Royal Hobart Hospital, Hobart, TAS, Australia.

Jordana Hughes (J)

CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia.

Jae-Kwan Jun (JK)

CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia.

Anneke van der Walt (A)

Central Clinical School, Monash University, Melbourne, VIC, Australia The Alfred, Melbourne, VIC, Australia.
ORCID: 0000-0002-4278-7003

Tim Spelman (T)

Central Clinical School, Monash University, Melbourne, VIC, Australia.

Helmut Butzkueven (H)

Central Clinical School, Monash University, Melbourne, VIC, Australia/The Alfred, Melbourne, VIC, Australia/Department of Neurology, Box Hill Hospital, Melbourne, VIC, Australia.

Tomas Kalincik (T)

CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia/Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia/L4 Centre, Melbourne Brain Centre at Royal Melbourne Hospital, Parkville, VIC, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Risk of secondary progressive multiple...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Risk of secondary progressive multiple...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Risk of secondary progressive multiple...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Risk of secondary progressive multiple...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études longitudinales › Risk of secondary progressive multiple...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Sclérose en plaques chronique progressive › Risk of secondary progressive multiple...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladies auto-immunes du système nerveux › Maladies démyélinisantes auto-immunes du SNC › Sclérose en plaques › Sclérose en plaques récurrente-rémittente › Risk of secondary progressive multiple...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Risk of secondary progressive multiple...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes de santé › Indicateurs d'état de santé › Acuité des besoins du patient › Indice de gravité de la maladie › Risk of secondary progressive multiple...